The legal dispute originated in 2018 when Corcept sued Teva over its plans to market a generic version of Korlym, the primary treatment for patients with Cushing’s syndrome. Corcept had sought to block the entry of lower-cost alternatives, alleging that Teva’s generic application infringed on its existing patents. However, the appellate court affirmed a 2023 ruling in favor of Teva, effectively removing the primary legal barrier to generic competition.

Market reaction was swift and severe, with Corcept shares falling 18% to $32.60 during Thursday trading. The stock hit a 52-week low of $28.66 at its floor, marking a period of intense volatility for the company. Over the past 12 months, Corcept has seen its market valuation cut in half as the legal uncertainty surrounding its core revenue driver intensified.

Antitrust Allegations and Monopoly Claims

The conflict between the two pharmaceutical firms is likely to persist beyond this patent ruling. Teva has filed a countersuit against Corcept, alleging the company has engaged in anticompetitive behavior to maintain a monopoly over the market for Cushing’s syndrome treatments. According to the report, Teva claims Corcept’s legal and marketing strategies were designed to stifle competition, a charge that adds significant regulatory risk to Corcept’s outlook even as it loses its patent protections.